How imatinib changed cancer treatment

John notes imatinib's later development as a targeted inhibitor of BCR-ABL and its transformative impact on treating CML.

Play episode from 08:13

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!